|
The Cochrane Collaboration
Cochrane Reviews |
| Explore | New + Updated | Other languages |
|
|
|
Colchicine for acute goutSchlesinger N, Schumacher R, Catton M, Maxwell L SummaryColchicine for acute goutThis summary of a Cochrane review presents what we know from research about the effect of colchicine for gout. The review shows that: There is silver level evidence (www.cochranemsk.org) that to treat gout, 1 mg of colchicine followed by 0.5 mg every two hours taken within 12 to 24 hours of an attack may decrease pain, swelling, redness and tenderness. Colchicine may cause side effects such as nausea, vomiting and diarrhea. It is not known whether colchicine is better than other treatments for gout.
What is gout and how can it be treated?
What are the results of this review?
Benefits of colchicine colchicine may improve pain more than placebo * pain may improve by 34 more points on a scale of 0 to 100 with colchicine colchicine may improve the symptoms of gout overall (such as pain, swelling, redness and tenderness) more than placebo * symptoms may improve by 3.6 more points on a scale of 0 to 12 with colchicine colchicine may improve the symptoms of gout faster There were no studies that compared colchicine to other treatments for gout. Harms of colchicine
This is a Cochrane review abstract and plain language summary, prepared and maintained by The Cochrane Collaboration, currently published in The Cochrane Database of Systematic Reviews 2010 Issue 1, Copyright © 2010 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
This version first published online:
October 18. 2006 AbstractBackgroundGout is one of the most common rheumatic diseases worldwide. Colchicine is regarded as beneficial in the treatment of acute gout, but has a high frequency of gastrointestinal adverse events. ObjectivesTo evaluate the efficacy and safety of colchicine for relief of the signs and symptoms of acute gouty arthritis, compared to placebo and other treatment interventions. Search strategyWe searched the following electronic databases to March 2006: Cochrane Central Register of Controlled Trials (CENTRAL, Issue 1, 2006), MEDLINE (from 1966), EMBASE (from 1980), CINAHL (from 1982), AMED (from 1985), Web of Science (from 1945) and Current Controlled Trials. Selection criteriaPublished randomised controlled trials (RCTs) and controlled clinical trials evaluating symptom relief and adverse outcomes of colchicine therapy in acute gout were considered for this review. Data collection and analysisTwo reviewers independently screened search results for inclusion, collected the data in a standardized form and assessed the methodological quality of the trial using validated criteria. Results for continuous outcome measures were expressed as weighted mean differences. Dichotomous outcome measures were pooled using relative risk. The number needed to treat was calculated for significant outcomes. Main resultsOne RCT (N=43) comparing colchicine to placebo for the treatment of acute gout was included in this review. The results favour the use of colchicine over placebo with an absolute reduction of 34% for pain and a 30% reduction in clinical symptoms such as tenderness on palpation, swelling, redness, and pain. The number needed to treat (NNT) with colchicine versus placebo to reduce pain was 3 and the NNT to reduce clinical symptoms was 2. All participants treated with colchicine experienced gastrointestinal side effects (diarrhea and/or vomiting) and the number needed to harm (NNH) with colchicine versus placebo was 1. No studies comparing colchicine to NSAIDs or other treatments such as corticosteroids or ACTH were identified. Authors' conclusionsColchicine is an effective treatment for the reduction of pain and clinical symptoms in patients experiencing acute attacks of gout, although in the regimen studied its low benefit to toxicity ratio limits its usefulness. It should be used as a second line therapy when NSAIDs or corticosteroids are contraindicated or ineffective. More evidence is needed to compare the efficacy of colchicine to that of NSAIDs or corticosteroids, the current first line therapy for acute gout. |